Estrogen Receptorα(ERα)陽性の前立腺癌の検討

@inproceedings{2000EstrogenR,
  title={Estrogen Receptor$\alpha$(ER$\alpha$)陽性の前立腺癌の検討},
  author={伊藤 貴章 and 古里 征国 and 山本 真也 and 間宮 良美 and 相澤 卓 and 三木 誠 and 金 泰正 and 石橋 啓一郎},
  year={2000}
}
Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor.
TLDR
The biological reports leading up to the structural conformation of a second ER ligand-binding site are summarized, the ERbeta LBD structure bound with two HT molecules to other ER structures are compared, and the potential for small molecular inhibitors designed to directly inhibit ER- coactivator and nuclear receptor (NR)-coactivator interactions are discussed.
Roles of Multifunctional COP9 Signalosome Complex in Cell Fate and Implications for Drug Discovery
TLDR
This review mainly summarizes the roles of CSN in cell cycle regulation, signal transduction and apoptosis, and its potential as diagnostic biomarkers, drug targets for cancer and infectious diseases.
Effects-Directed Analysis of Sediments From Polluted Marine Sites in Norway
TLDR
The environmental status of two polluted marine sites in Norway was investigated by a combination of target chemical analysis and effect-directed analysis (EDA) and the aryl hydrocarbon receptor (AhR) agonist activity in extracts of sediments from marine sites close to Oslo, Oslo harbor, and Grenland showed elevated levels of activity.
Pure oestrogen antagonists for the treatment of advanced breast cancer.
  • A. Howell
  • Biology, Medicine
    Endocrine-related cancer
  • 2006
TLDR
Fulvestrant is the only oestrogen antagonist with no agonistic effects licensed for the treatment of advanced breast cancer in postmenopausal women and there are extensive data to support the lack of partial agonist effects of fulvestrant and, importantly, its lack of cross-resistance with tamoxifen.